Pfizer Inc

NYSE:PFEUnited States

May 13, 2024

Show headlines and story abstract

• DJ France Secures $16 Bln From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update, from 9:40AM ET on Monday May 13, 2024 by Dow Jones

  9:40AM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: JPM, MSFT, MS, PFE, SNY, ACN, AMZN, AZN
  By Mauro Orru France bagged 15 billion euros ($16.16 billion) of investment commitments from U.S. tech giants and other companies at a summit just outside of Paris, underscoring a push from President Emmanuel Macron to promote the country as an attractive destination for international investors. Microsoft, Amazon.com, Pfizer and AstraZeneca were among the top investors at the Choose France summit held at the Palace of Versailles. Dubbed France's mini Davos, the event draws high-profile executives willing to pour funds into the French economy. Macron launched the summit in 2018 during his first term as president in an effort to portray France as an attractive hub for foreign investors. In a post on X, he said this year's summit would bring in a record EUR15 billion in investments and create 10,000 new jobs. Paris has long lagged behind major financial centers like New York, but the amount in investment commitments marks an endorsement of France as a key hub for many foreign investors in Europe. The country ranks as the most attractive in Europe for international investors, according to a recent EY survey, putting it ahead of Germany and the U.K. The survey concluded that most respondents, particularly those outside of or not yet established in France, believe the country will become more attractive over the next three years. On Monday, Microsoft President Brad Smith said the tech giant would invest EUR4 billion to build out artificial-intelligence, data-center and cloud infrastructure in the country. Russ Grandinetti, senior vice president of international stores at Amazon, said the e-commerce giant would invest more than EUR1.2 billion to bolster its Amazon Web Services cloud infrastructure, logistics infrastructure and artificial intelligence. JPMorgan Chase, Morgan Stanley, Accenture and the Qatar Investment Authority also made a number of investment commitments. On the pharmaceutical front, Pfizer France President Reda Guiha said the country had developed a solid biopharmaceutical ecosystem that was benefiting innovation in fields like oncology. The maker of the Covid-19 vaccine is investing EUR500 million as part of a five-year plan to strengthen research and development. Sanofi, the French pharma group, will spend more than EUR1 billion on ramping up ramping up production capability. Meanwhile, Anglo-Swedish rival AstraZeneca said it would pour $388 million to further develop its production site in Dunkirk, northern France. Write to Mauro Orru at mauro.orru@wsj.com (END) Dow Jones Newswires May 13, 2024 09:40 ET (13:40 GMT)

• DJ France Secures $16 Bln From Microsoft, Amazon and Others at Foreign Investment Summit -- Update, from 9:05AM ET on Monday May 13, 2024 by Dow Jones

  9:05AM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: MSFT, PFE, SNY, AMZN, AZN
  
  By Mauro Orru
  
  France bagged 15 billion euros ($16.16 billion) of investment commitments from U.S. tech giants and other companies at a summit just outside of Paris, underscoring a push from President Emmanuel Macron to promote the country as an attractive destination for international investors.
  

• ViiV Healthcare Announces Health Canada Approval for APRETUDE (Cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV, from 8:01AM ET on Monday May 13, 2024 by CNW Group

  8:01AM ET on Monday May 13, 2024 by CNW Group
  Companies Mentioned: PFE

  COMTEX_452301011/2669/2024-05-13T08:01:31

• Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting, from 8:00AM ET on Monday May 13, 2024 by PR Newswire

  8:00AM ET on Monday May 13, 2024 by PR Newswire
  Companies Mentioned: PFE

  16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers

  Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology(ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

• Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting, from 8:00AM ET on Monday May 13, 2024 by Dow Jones

  8:00AM ET on Monday May 13, 2024 by Dow Jones
  Companies Mentioned: ALPMY, PFE
  impact of treatment suspension Abstract Number: 5005 (TxS) on health- related Date: June 1, 2024 quality of life (HRQoL) 3:00-6:00PM CDT ------------------------------ ------------------ -------------------------- EMBARK post hoc analysis of S. Freedland Type: Poster Presentation sexual activity (SA) Abstract Number: 5084 patient-reported outcomes Date: June 2, 2024 (PROs) in patients (pts) who 9:00 AM-12:00 PM CDT were sexually active or interested in sex at baseline (BL) ------------------------------ ------------------ -------------------------- Physicians use of first-line S. Loeb Type: Poster Presentation treatment intensification in Abstract Number: 5087 metastatic castration- Date: June 2, 2024 sensitive prostate cancer 9:00 AM-12:00 PM CDT (mCSPC): A discrete choice experiment ------------------------------ ------------------ -------------------------- Characteristics and treatment A. Morgans Type: Online-Only Abstract (Tx) patterns (TxP) of Abstract Number: e17071 high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT) ------------------------------ ------------------ -------------------------- Zolbetuximab ------------------------------------------------------------------------------ Presentation Title Lead Author Presentation Details ------------------------------ ------------------ -------------------------- Final overall survival results K. Shitara Type: Poster Presentation from phase 3 SPOTLIGHT study Abstract Number: 4036 evaluating zolbetuximab + Date: June 1, 2024 mFOLFOX6 as first-line (1L) 1:30-4:30 PM CDT treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma ------------------------------ ------------------ --------------------------